Invention Grant
- Patent Title: Therapeutic targets involved in the progression of nonalcoholic steatohepatitis (NASH)
-
Application No.: US16094111Application Date: 2017-04-18
-
Publication No.: US12285464B2Publication Date: 2025-04-29
- Inventor: Ira Tabas , Xiaobo Wang , Omid Farokhzad , Xiaoding Xu
- Applicant: The Trustees of Columbia University in the City of New York , The Brigham and Women's Hospital, Inc.
- Applicant Address: US NY New York; US MA Boston
- Assignee: The Trustees of Columbia University in the City of New York,The Brigham and Women's Hospital, Inc.
- Current Assignee: The Trustees of Columbia University in the City of New York,The Brigham and Women's Hospital, Inc.
- Current Assignee Address: US NY New York; US MA Boston
- Agency: Bryan Cave Leighton Paisner LLP
- International Application: PCT/US2017/028109 WO 20170418
- International Announcement: WO2017/184586 WO 20171026
- Main IPC: C12N15/113
- IPC: C12N15/113 ; A61K9/1271 ; A61K9/50 ; A61K31/4178 ; A61K31/4439 ; A61K31/7105 ; A61K31/713 ; A61K38/17 ; A61K47/69 ; A61K48/00 ; A61P1/16 ; G01N33/50 ; G01N33/68 ; A61K45/06
Abstract:
The present invention relates to methods and compositions for specifically modulating the Hippo pathway transcription factor TAZ (WWTR1), as a therapeutic target for inhibiting or preventing liver conditions including the progression of steatosis-to-NASH in a patient.
Public/Granted literature
- US20190255143A1 THERAPEUTIC TARGETS INVOLVED IN THE PROGRESSION OF NONALCOHOLIC STEATOHEPATITIS (NASH) Public/Granted day:2019-08-22
Information query
IPC分类:
